Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Breast Neoplasms 24Prostatic Neoplasms 16Sarcoma 9Carcinoma, Non-Small-Cell Lung 9Lung Neoplasms 5Uterine Cervical Neoplasms 4Endometrial Neoplasms 4Squamous Cell Carcinoma of Head and Neck 3Liposarcoma, Myxoid 3Head and Neck Neoplasms 3Glioblastoma 3Triple Negative Breast Neoplasms 2Small Cell Lung Carcinoma 2Sarcoma, Synovial 2Radiation Injuries 2Pancreatic Neoplasms 2Neurofibrosarcoma 2Neoplasms 2Melanoma 2Lymphatic Metastasis 2Liposarcoma 2Leiomyosarcoma 2Histiocytoma, Malignant Fibrous 2Fibrosarcoma 2Carcinoma, Intraductal, Noninfiltrating 2Breast Carcinoma In Situ 2Advanced Refractory Solid Tumors 2Uterine Neoplasms 1Urothelial Cancer 1Urogenital Neoplasms 1

Interventions

Gemcitabine 2Cystectomy 2Cisplatin 2transplatin 1pembrolizumab 1pegfilgrastim 1Radiotherapy 1Radiation Dose Hypofractionation 1Radiation 1Platinum 1Chemoradiotherapy 11,2-diaminocyclohexaneplatinum II citrate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Infiltrating Bladder Urothelial Carcinoma × Radiation Dose Hypofractionation × Clear all
NCT03419130 2018-12-07

Radiation Therapy and Pembrolizumab in Treating Patients With Localized Urothelial Bladder Cancer

University of California, San Francisco

Phase 2 Withdrawn
Genitourinary

Infiltrating Bladder Urothelial Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡